On Saturday April 27th 2013, the 2012 Lindy Fraser Memorial Award was presented to Dr. David Goltzman at the annual CaMos meeting in Montreal. Osteoporosis Canada would like to congratulate Dr. Goltzman!
Osteoporosis Canada established this award in 1993. This prestigious award recognizes individuals who have done exemplary research and have helped to increase the knowledge about osteoporosis. The recipient is nominated by members of our Scientific Advisory Council.
Photo (From left to right): Dr. Angela Cheung, Dr. Famida Jiwa and Dr. David Goltzman.
Dr. Famida Jiwa, President & CEO, Osteoporosis Canada salutes volunteers from coast to coast.
“From a grateful President and CEO to all of you - thank you! Without you, Osteoporosis Canada would cease to be. I am extremely proud to work alongside you as our organization moves ever more forward in assisting those with osteoporosis who have fractured to receive the assessment and treatment necessary to live full and productive lives. It’s a focus that we have demonstrated, through initiatives such as Make your FIRST break your LAST and Stand Tall Canada, we can all stand behind.
Take some time during this week to celebrate the great strides that our organization has made throughout its 31 years because these accomplishments were achieved thanks to the hard work and vision of volunteers like you. With your support, we anticipate many more successes in the year ahead.
Once again, a heartfelt thank you for your generous gifts of time, talent and perspective. To say you are fabulous barely covers it, but you are and I salute you!
Sincerely,
Famida Jiwa
President & CEO, Osteoporosis Canada”
Osteoporosis Canada would like to recognize Dr. Bill Leslie and his work with the ISCD (International Society for Clinical Densitometry). Bill recently became the Chair of the Canadian Panel and the Vice President of ISCD. His abstract, coauthored by SAC consultants Drs. Suzanne Morin and Su mit Majumdar, was also honoured with the 2013 Best Clinician Abstract Award. Congratulations Bill!
A recent report by the US Preventive Services Task Force (USPSTF) suggests that low doses of vitamin D up to 400 IU daily and calcium supplements up to 1000 mg daily are not effective in reducing the risk of fracture in healthy people (that is, people without osteoporosis or fractures). Based on all research to date, Osteoporosis Canada still recommends that those with osteoporosis or fractures who are 50 years of age or more take 1200 mg of elemental calcium daily, preferably from dietary sources, and 800-2000 IU of a vitamin D supplement daily.
Recently concern has been raised regarding potential increased risk of coronary events in association with calcium supplements. The research studies which have been completed have been relatively small and have been of less than ideal design. Further research with large well designed studies is needed. Osteoporosis Canada recommends that daily intake of calcium be obtained largely from dietary sources. If this is not possible then supplements may be used preferably calcium carbonate or calcium citrate following discussion with your doctor regarding the safe dose for each individual.
Congratulations to Dr. Famida Jiwa, the President and CEO of Osteoporosis Canada, who has recently been re-elected to the position of Chair of the Patient Societies Subcommittee of the CNS of the IOF for a 3rd term of two years, effective December 2012.
Effective December 1st, the Alberta Drug Benefits Listing has included Aclasta under Special Authorization criteria. The Alberta Drug Benefit List defines the prescription drugs and drug products covered by the ministry's supplemental health plans.
Related News:
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
**Effective December 1st, the Alberta Drug Benefits Listing has included Aclasta under Special Authorization criteria.
We are aware of recent media reports about the potential link between Prolia and atypical fractures.
Connect With Us